Leadership
The Intelligent Bio Solutions management team, scientific team and board of Directors have significant global experience in the development of pharmaceuticals, medical devices and product launches.
Leadership Team
Harry Simeonidis
President & CEO
Mr. Simeonidis has more than 25 years of experience in healthcare, pharmaceutical and life sciences across various senior management positions throughout Asia, Australia and New Zealand. Before joining Intelligent Bio Solutions, he was the General Manager, Surgery, Asia Pacific, at GE Healthcare where he oversaw significant expansion of the business’ market share. Prior to this, Harry spent nine years as the President and CEO of GE Healthcare ANZ.
Spiro Sakiris
Chief Financial Officer
Mr. Sakiris has 34 years’ experience in accounting and taxation, IPOs and capital raising, and business system designs, including the application of IFRS and US GAAP for the life science industry. Mr. Sakiris is a member of the Institute of Chartered Accountants of Australia & New Zealand.
Doug Heath
Vice President of Global Sales
Peter Passaris
Vice President of Product Development
Anna Turkington
Vice President of Marketing
Rafael
Da Luz
Vice President of Regulatory Affairs
Callistus Sequeira
Vice President of Global Quality & Operations
Ghanshyam Poudel
Finance Director
Board of Directors
Dr. Steven Boyages
M.D., MB, BS, Ph.D
Chairman of the Board
A practicing clinician in endocrinology with more than 30 years’ experience in medicine, including multiple executive positions, Dr. Steven Boyages serves as Chairman of the Intelligent Bio Solutions Board. Dr. Boyages previously held the position of Chief Executive of the Sydney West Area Health Service (SWAHS), which is now known as Western Sydney Local Health District. Covering a population of 1.2 million people, SWAHS employed more than 15,000 staff and had a gross operating budget of $2 billion (AUD), managing $1.6 billion (AUD) worth of assets. Dr. Boyages has also served as Medical Director for eHealth New South Wales, and was the foundation Chief Executive of the Clinical Education and Training Institute (CETI) New South Wales (NSW), Australia, set up to ensure the development and the delivery of clinical education and training across the NSW public health system.
Previous to this, Dr. Boyages was the Director of Diabetes and Endocrinology at Westmead Hospital, from 1990 to 1999. During this time, Dr. Boyages’ major achievements were to define the pathophysiology of thyroid hormone deficiency on brain development secondary to iodine deficiency; to develop prevention strategies in iodine deficient communities in China, India, Indonesia and Northern Italy; to define the impact of growth hormone excess and deficiency in adults and to develop innovative population health models of care for people with diabetes. Dr. Boyages continues an active research career in a range of fields, but mostly in the pursuit of better models of chronic disease prevention and management.
Dr. Boyages was the foundation director of the Centre for Research and Clinical Policy in NSW Health in 1999, during which he established the Priority Health Programs (receiving $15 million (AUD) in funding per annum), doubled the Research Infrastructure Grants Program, established the Quality Branch of NSW Health and was appointed as Clinical Advisor to the Director General to implement the Government Action Plan for Health Reform. Additionally, Dr. Boyages was instrumental in establishing and securing funding for the NSW biotechnology strategy, BioFirst, a $150 (AUD) million investment.
Nicola Fraser
Chair, Audit Committee (Independent)
Nicola Fraser is currently the Managing Partner of NextKey Services LLC, a financial consulting company she co-founded in 2019 that advises high-growth companies on strategic financial matters. From 2015 to 2018, prior to founding NextKey, Ms. Fraser served as Executive Director – Finance, Regulatory Capital at JP Morgan Chase. While at JP Morgan Chase and in her previous senior executive positions at Fannie Mae and Deloitte, she led significant financial transformations and regulatory compliance initiatives. Ms. Fraser is an active CPA, licensed in Texas, and holds an AICPA Chartered Global Management Accountant (CGMA) designation.
Jason Isenberg
Director (Independent)
Jason Isenberg currently serves as Assistant General Counsel for RFA Management Company, LLC in Atlanta, Georgia, where he advises a large, endowment-style portfolio in matters including corporate governance, corporate and real estate transactions, business operations, employment law and risk mitigation. Jason successfully negotiated strategic transactions exceeding $500,000,000. He obtained his Bachelor of Arts from the University of Maryland and his Juris Doctor from New England Law in Boston.
Mr Jonathan Hurd
CAMS
Director (Independent)
Mr. Hurd has been a member of the Intelligent Bio Solutions Board of Directors since April 2018, serving as our Chairman of the Board from August 2018 to November 2019. Mr. Hurd has expertise in broker-dealer and investment advisory regulations and is experienced in FINRA and SEC rules and regulations. Mr. Hurd has served as Founder and CEO at Asgard Regulatory Group, or “Asgard,” since founding the firm in 2008. Mr. Hurd was also a Supervisor of Examiners at FINRA, previously NASD, in the New York District Office. While with FINRA, he supervised routine examinations of FINRA member firms, and conducted large-scale enforcement cases jointly with the Justice Department and Federal Bureau of Investigations. Mr. Hurd is also a Certified Anti-Money Laundering Specialist (CAMS) and holds the Series 7, 24, 27, 53, 55, 63, 66, 79 and 99 licenses as well as his NYS Life and Health Insurance licenses.